Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Citi
Johnson and Johnson
Healthtrust
Teva
UBS
Federal Trade Commission
Fuji
QuintilesIMS

Generated: May 27, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021700

« Back to Dashboard

NDA 021700 describes AVANDARYL, which is a drug marketed by Sb Pharmco and is included in one NDA. There is one patent protecting this drug and two Paragraph IV challenges. Additional details are available on the AVANDARYL profile page.

The generic ingredient in AVANDARYL is glimepiride; rosiglitazone maleate. There are fifteen drug master file entries for this compound. Additional details are available on the glimepiride; rosiglitazone maleate profile page.
Summary for 021700
Tradename:AVANDARYL
Applicant:Sb Pharmco
Ingredient:glimepiride; rosiglitazone maleate
Patents:1
Formulation / Manufacturing:see details

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength1MG;4MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Nov 23, 2005TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Oct 19, 2020Product Flag?Substance Flag?Delist Request?Y

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength2MG;4MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Nov 23, 2005TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Oct 19, 2020Product Flag?Substance Flag?Delist Request?Y

Profile for product number 003

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength4MG;4MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Nov 23, 2005TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Oct 19, 2020Product Flag?Substance Flag?Delist Request?Y

Expired US Patents for NDA 021700

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sb Pharmco AVANDARYL glimepiride; rosiglitazone maleate TABLET;ORAL 021700-003 Nov 23, 2005 ➤ Try a Free Trial ➤ Try a Free Trial
Sb Pharmco AVANDARYL glimepiride; rosiglitazone maleate TABLET;ORAL 021700-002 Nov 23, 2005 ➤ Try a Free Trial ➤ Try a Free Trial
Sb Pharmco AVANDARYL glimepiride; rosiglitazone maleate TABLET;ORAL 021700-001 Nov 23, 2005 ➤ Try a Free Trial ➤ Try a Free Trial
Sb Pharmco AVANDARYL glimepiride; rosiglitazone maleate TABLET;ORAL 021700-003 Nov 23, 2005 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Daiichi Sankyo
Chinese Patent Office
Dow
UBS
Johnson and Johnson
QuintilesIMS
Farmers Insurance
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.